Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization

MOTIVATION Several mathematical models have been investigated for the description of viral dynamics in the human body: HIV-1 infection is a particular and interesting scenario, because the virus attacks cells of the immune system that have a role in the antibody production and its high mutation rate permits to escape both the immune response and, in some cases, the drug pressure. The viral genetic evolution is intrinsically a stochastic process, eventually driven by the drug pressure, dependent on the drug combinations and concentration: in this article the viral genotypic drug resistance onset is the main focus addressed. The theoretical basis is the modelling of HIV-1 population dynamics as a predator-prey system of differential equations with a time-dependent therapy efficacy term, while the viral genome mutation evolution follows a Poisson distribution. The instant probabilities of drug resistance are estimated by means of functions trained from in vitro phenotypes, with a roulette-wheel-based mechanisms of resistant selection. Simulations have been designed for treatments made of one and two drugs as well as for combination antiretroviral therapies. The effect of limited adherence to therapy was also analyzed. Sequential treatment change episodes were also exploited with the aim to evaluate optimal synoptic treatment scenarios. RESULTS The stochastic predator-prey modelling usefully predicted long-term virologic outcomes of evolved HIV-1 strains for selected antiretroviral therapy combinations. For a set of widely used combination therapies, results were consistent with findings reported in literature and with estimates coming from analysis on a large retrospective data base (EuResist).

[1]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[2]  V. Volterra.  Variations and Fluctuations of the Number of Individuals in Animal Species living together , 1928 .

[3]  C. Perno,et al.  The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART , 2004 .

[4]  A N Phillips,et al.  Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development , 2001, AIDS.

[5]  P. Narciso,et al.  Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients , 2005, AIDS.

[6]  Michael de la Maza,et al.  Book review: Genetic Algorithms + Data Structures = Evolution Programs by Zbigniew Michalewicz (Springer-Verlag, 1992) , 1993 .

[7]  A. Collier,et al.  Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen , 2007, AIDS.

[8]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[9]  W. Cleveland.  LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression , 1981 .

[10]  M. Kimura.  The Neutral Theory of Molecular Evolution: Introduction , 1983 .

[11]  Massimo Bernaschi,et al.  Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infection. , 2004, AIDS research and human retroviruses.

[12]  A. Perelson,et al.  A model of HIV-1 pathogenesis that includes an intracellular delay. , 2000, Mathematical biosciences.

[13]  Hulin Wu,et al.  Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. , 2003, Mathematical biosciences.

[14]  Yang Wang,et al.  Substitution Model of Sequence Evolution for the Human Immunodeficiency Virus Type 1 Subtype B gp120 Gene over the C2-V5 Region , 2001, Journal of Molecular Evolution.

[15]  James E. Baker,et al.  Reducing Bias and Inefficienry in the Selection Algorithm , 1987, ICGA.

[16]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[17]  Hulin Wu,et al.  A Comparison Study of Models and Fitting Procedures for Biphasic Viral Dynamics in HIV‐1 Infected Patients Treated with Antiviral Therapies , 2000, Biometrics.

[18]  S Bonhoeffer,et al.  A stochastic model for primary HIV infection: optimal timing of therapy. , 1999, AIDS.

[19]  Massimo Bernaschi,et al.  Optimization of HAART with genetic algorithms and agent-based models of HIV infection , 2007, Bioinform..

[20]  Massimo Bernaschi,et al.  HIV-1 Strategies of Immune Evasion , 2005 .

[21]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[23]  Matteo Bianchi,et al.  Modelling and control of HIV dynamics , 2008, Comput. Methods Programs Biomed..

[24]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[25]  Niko Beerenwinkel,et al.  A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. , 2006, Biostatistics.

[26]  S Kumar,et al.  Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history , 1997 .

[27]  Alan S. Perelson,et al.  Viral and Latent Reservoir Persistence in HIV-1–Infected Patients on Therapy , 2006, PLoS Comput. Biol..

[28]  Yves Moreau,et al.  Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment , 2008, Bioinform..

[29]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[30]  Y X Fu,et al.  Estimating mutation rate and generation time from longitudinal samples of DNA sequences. , 2001, Molecular biology and evolution.

[31]  Thomas Lengauer,et al.  Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes , 2003, Nucleic Acids Res..

[32]  Zbigniew Michalewicz,et al.  Genetic Algorithms + Data Structures = Evolution Programs , 1996, Springer Berlin Heidelberg.

[33]  W. Tan,et al.  A stochastic model for drug resistance in AIDS chemotherapy and the HIV incubation distribution , 1995 .

[34]  P. Verhulst.  Recherches mathématiques sur la loi d’accroissement de la population , 1845, Nouveaux mémoires de l'Académie royale des sciences et belles-lettres de Bruxelles.

[35]  M. Lederman,et al.  Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. , 1999, The Journal of infectious diseases.

[36]  M. Kimura,et al.  The neutral theory of molecular evolution. , 1983, Scientific American.

[37]  John J. Grefenstette,et al.  Genetic algorithms and their applications , 1987 .

[38]  Robert W. Shafer,et al.  Drug Resistance and Heterogeneous Long-Term Virologic Responses of Human Immunodeficiency Virus Type 1-Infected Subjects to Zidovudine and Didanosine Combination Therapy , 1995 .